JPH08291082A - Composition for prophylaxis of secondary cardioattack - Google Patents
Composition for prophylaxis of secondary cardioattackInfo
- Publication number
- JPH08291082A JPH08291082A JP8098084A JP9808496A JPH08291082A JP H08291082 A JPH08291082 A JP H08291082A JP 8098084 A JP8098084 A JP 8098084A JP 9808496 A JP9808496 A JP 9808496A JP H08291082 A JPH08291082 A JP H08291082A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- hydroxybutanoic acid
- derivative
- pravastatin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、二次心臓発作(sec
ond heart attack)の予防用組成物、更に詳しくは、酵
素3−ヒドロキシ−3−メチルグルタリルコエンチーム
A(HMG CoA)レダクターゼの抑制剤(以下、HMG
CoAレダクターゼ抑制剤と称す)(たとえばプラバス
タチン)単独、または該抑制剤とアンギオテンシン変換
酵素(ACE)抑制剤(以下、ACE抑制剤と称す)との組
合せから成る、実質的正常な血清コレステロール量を持
つ患者の二次心臓発作の危険の予防または軽減用組成物
に関する。TECHNICAL FIELD The present invention relates to a secondary heart attack (sec).
ond heart attack), more specifically, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (hereinafter referred to as HMG).
It has a substantially normal serum cholesterol level consisting of a CoA reductase inhibitor (for example, pravastatin) alone or a combination of the inhibitor and an angiotensin converting enzyme (ACE) inhibitor (hereinafter referred to as ACE inhibitor). A composition for preventing or reducing the risk of a second heart attack in a patient.
【0002】[0002]
【発明の構成と効果】本発明によれば、実質的正常な血
清コレステロール量を持つ哺乳動物の二次心臓発作の徴
候を抑制したりあるいは該発作の危険を軽減したりする
組成物が提供され、ここで該組成物はHMG CoAレ
ダクターゼ抑制剤単独、または該抑制剤とACE抑制剤
との組合せから成る。これらの薬効成分の治療上有効量
を、実質的正常な血清コレステロール量を持つ哺乳動物
に対して、全身投与、たとえば経口または非経口投与す
ることができる。According to the present invention, there is provided a composition for suppressing the symptoms of a secondary heart attack or reducing the risk of such a stroke in a mammal having a substantially normal serum cholesterol level. , Wherein the composition comprises the HMG CoA reductase inhibitor alone or in combination with the inhibitor and an ACE inhibitor. A therapeutically effective amount of these medicinal ingredients can be systemically administered, eg, orally or parenterally, to a mammal having a substantially normal serum cholesterol level.
【0003】本発明によって治療される患者が正常血圧
性である好ましい具体例において、ACE抑制剤を用い
る場合、その投与量は血行作用を起すのに必要な量より
少ない、すなわち、血圧の降下を起すのに必要な量より
も少ないことが好ましい。HMG CoAレダクターゼ
抑制剤とACE抑制剤を組合せて用いる場合、その重量
割合は約0.001:1〜1000:1、好ましくは約0.
05:1〜100:1の範囲内で選定される。In a preferred embodiment, in which the patient treated according to the invention is normotensive, when an ACE inhibitor is used, its dose is less than that required to produce a hemodynamic effect, ie a decrease in blood pressure. It is preferably less than the amount required to raise it. When the HMG CoA reductase inhibitor and the ACE inhibitor are used in combination, the weight ratio is about 0.001: 1 to 1000: 1, preferably about 0.001.
It is selected within the range of 05: 1 to 100: 1.
【0004】HMG CoAレダクターゼ抑制剤は、単
独またはACE抑制剤と組合せて、初期心筋梗塞後でき
るだけ早く投与される。語句「実質的正常な血清コレス
テロール量」とは、総コレステロール(TC)が200m
g/dl以下、好ましくは190mg/dl以下を指称
する。HMG CoA reductase inhibitors, alone or in combination with ACE inhibitors, are administered as soon as possible after early myocardial infarction. The phrase "substantially normal serum cholesterol level" refers to total cholesterol (TC) of 200 m
It is g / dl or less, preferably 190 mg / dl or less.
【0005】[0005]
【発明の実施の形態】本発明での使用に好適なHMG
CoAレダクターゼ抑制剤としては、これらに限定され
るものではないが、メバスタチンおよびU.S.特許N
o.3983140に開示の関連化合物、ロバスタチン
(メビノリン)およびU.S.特許No.4231938に
開示の関連化合物、プラバスタチンおよびU.S.特許N
o.4346227に開示の関連化合物、ベロスタチン
(シンビノリン)およびU.S.特許No.4448784
および4450171に開示の関連化合物が包含され、
ロバスタチン、プラバスタチンまたはベロスタチンが好
ましい。本発明で使用しうる他のHMG CoAレダク
ターゼ抑制剤としては、これらに限定されるものではな
いが、フルインドスタチン(サンド(Sandoz)XU−62
−320)、U.S.特許No.4613610に開示のメ
バロノラクトン誘導体のピラゾール類縁体、PCT出願
WO86/03488に開示のメバロノラクトン誘導体
のインデン類縁体、U.S.特許No.4647576に
開示の6−[2−(置換ピロール−1−イル)アルキル]ピ
ラン−2−オンおよびその誘導体、サール(Searle)の
SC−45355(3−置換ペンタンジ酸誘導体)ジクロ
ロアセテート、PCT出願WO86/07054に開示
のメバロノラクトンのイミダゾール類縁体、フランス特
許No.2596393に開示の3−カルボキシ−2−
ヒドロキシ−プロパン−ホスホン酸誘導体、ヨーロッパ
特許出願No.0221025に開示の2,3−ジ置換ピ
ロール、フランおよびチオフェン誘導体、U.S.特許N
o.4686237に開示のメバロノラクトンのナフチ
ル類縁体、U.S.特許No.4499289に開示のオ
クタヒドロ−ナフタレン類、ヨーロッパ特許出願No.
0142146A2に開示のメビノリン(ロバスタチン)
のケト類縁体、並びに他の公知のHMG CoAレダク
ターゼ抑制剤が包含される。DETAILED DESCRIPTION OF THE INVENTION HMG Suitable for Use in the Invention
CoA reductase inhibitors include, but are not limited to, mevastatin and US Pat.
Lovastatin, a related compound disclosed in US Pat.
(Mevinolin) and related compounds disclosed in US Patent No. 4231938, pravastatin and US Patent N.
Related compounds disclosed in US Pat. No. 4,346,227, Velostatin
(Cymbinolin) and US Patent No. 4448784
And related compounds disclosed in 4450171 are included,
Lovastatin, pravastatin or verostatin are preferred. Other HMG CoA reductase inhibitors that can be used in the present invention include, but are not limited to, fluindostatin (Sandoz XU-62).
-320), the pyrazole analog of the mevalonolactone derivative disclosed in US Pat. No. 4613610, the indene analog of the mevalonolactone derivative disclosed in PCT application WO86 / 03488, the 6-disclosed in US Pat. No. 4647576. [2- (Substituted pyrrol-1-yl) alkyl] pyran-2-one and its derivatives, Searle's SC-45355 (3-substituted pentanedioic acid derivative) dichloroacetate, mevalonolactone disclosed in PCT application WO86 / 07054. Imidazole analogs, 3-carboxy-2-disclosed in French Patent No. 2596393
Hydroxy-propane-phosphonic acid derivatives, 2,3-disubstituted pyrrole, furan and thiophene derivatives disclosed in European Patent Application No. 0221025, US Pat.
Naphthyl analogs of mevalonolactone disclosed in US Pat. No. 4,686,237, octahydro-naphthalenes disclosed in US Pat. No. 4499289, European patent application No.
Mevinolin (lovastatin) disclosed in 0142146A2
And other known HMG CoA reductase inhibitors.
【0006】さらに、本発明での使用に好適な、HMG
CoAレダクターゼの抑制に用いるホスフィン酸化合
物は、GB2205837に開示される、式:Further, HMG suitable for use in the present invention
The phosphinic acid compounds used for the inhibition of CoA reductase are disclosed in GB 2205837 and have the formula:
【化1】 [式中、Xは−O−または−NH−、nは1または2お
よびZは疎水性アンカー(anchor)である]の成分を有す
る化合物である。Embedded image [Wherein X is -O- or -NH-, n is 1 or 2 and Z is a hydrophobic anchor].
【0007】かかる化合物の具体例としては、(S)−4
−[[[4'−フルオロ−3,3',5−トリメチル[1,1'−
ビフェニル]−2−イル]メトキシ]メトキシホスフィニ
ル]−3−ヒドロキシブタン酸メチルエステルまたはそ
のモノリチウム塩、(S)−4−[[[4'−フルオロ−3,
3',5−トリメチル[1,1'−ビフェニル]−2−イル]
メトキシ]ヒドロキシホスフィニル]−3−ヒドロキシブ
タン酸ジリチウム塩、(3S)−4−[[[4'−フルオロ−
3,3',5−トリメチル[1,1'−ビフェニル]−2−イ
ル]メトキシ]メチルホスフィニル]−3−ヒドロキシブ
タン酸モノリチウム塩、(S)−4−[[[2,4−ジクロロ
−6−[(4−フルオロフェニル)メトキシ]フェニル]メ
トキシ]メトキシホスフィニル]−3−ヒドロキシブタン
酸モノリチウム塩、(3S)−4−[[[2,4−ジクロロ−
6−[(4−フルオロフェニル)メトキシ]フェニル]メト
キシ]ヒドロキシホスフィニル]−3−ヒドロキシブタン
酸ジリチウム塩、(3S)−4−[[2,4−ジクロロ−6
−[(4−フルオロフェニル)メトキシ]フェニル]メトキ
シ]メチルホスフィニル]−3−ヒドロキシブタン酸また
はそのメチルエステル、および(S)−4−[[[[4'−フ
ルオロ−3,3',5−トリメチル[1,1'−ビフェニル−
2−イル]メチル]アミノ]メトキシホスフィニル]−3−
ヒドロキシブタン酸モノリチウム塩が包含される。Specific examples of such compounds include (S) -4
-[[[4'-Fluoro-3,3 ', 5-trimethyl [1,1'-
Biphenyl] -2-yl] methoxy] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester or its monolithium salt, (S) -4-[[[4'-fluoro-3,
3 ', 5-trimethyl [1,1'-biphenyl] -2-yl]
Methoxy] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt, (3S) -4-[[[4'-fluoro-
3,3 ′, 5-Trimethyl [1,1′-biphenyl] -2-yl] methoxy] methylphosphinyl] -3-hydroxybutanoic acid monolithium salt, (S) -4-[[[2,4 -Dichloro-6-[(4-fluorophenyl) methoxy] phenyl] methoxy] methoxyphosphinyl] -3-hydroxybutanoic acid monolithium salt, (3S) -4-[[[2,4-dichloro-
6-[(4-fluorophenyl) methoxy] phenyl] methoxy] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt, (3S) -4-[[2,4-dichloro-6]
-[(4-Fluorophenyl) methoxy] phenyl] methoxy] methylphosphinyl] -3-hydroxybutanoic acid or its methyl ester, and (S) -4-[[[[4'-fluoro-3,3 ' , 5-Trimethyl [1,1'-biphenyl-
2-yl] methyl] amino] methoxyphosphinyl] -3-
Hydroxybutanoic acid monolithium salt is included.
【0008】本発明での使用に好適な、別の種類のHM
G CoAレダクターゼ抑制剤としては、GB2205
838に開示のホスフィン酸化合物が包含され、該化合
物は式:Another type of HM suitable for use in the present invention
Examples of G CoA reductase inhibitors include GB2205
838, and a phosphinic acid compound disclosed in 838, wherein the compound has the formula:
【化2】 [式中、Xは−CH2−、−CH2−CH2−、−CH=C
H−、−CH2CH2CH2−、−C≡C−または−CH2
O−(この場合、OがZに結合)、およびZは疎水性アン
カーである]の成分を有する。Embedded image [Wherein, X is -CH 2 -, - CH 2 -CH 2 -, - CH = C
H -, - CH 2 CH 2 CH 2 -, - C≡C- or -CH 2
O- (where O is attached to Z), and Z is a hydrophobic anchor].
【0009】かかる化合物の具体例としては、(S)−4
−[[[1−(4−フルオロフェニル)−3−(1−メチルエ
チル)−1H−インドール−2−イル]エチニル]ヒドロ
キシホスフィニル]−3−ヒドロキシブタン酸またはそ
のナトリウム塩(SQ33600)(これが好ましい)もし
くはジリチウム塩;(S)−4−[[(E)−2−[4'−フル
オロ−3,3',5−トリメチル−[1,1'−ビフェニル]
−2−イル]エテニル]ヒドロキシホスフィニル]−3−
ヒドロキシブタン酸またはそのジリチウム塩;(S)−4
−[[2−[4'−フルオロ−3,3',5−トリメチル−
[1,1'−ビフェニル]−2−イル]エチル]ヒドロキシホ
スフィニル]−3−ヒドロキシブタン酸メチルエステル
またはそのモノもしくはジアルカリ金属塩;(S)−4−
[[[4'−フルオロ−3,3',5−トリメチル−[1,1'−
ビフェニル]−2−イル]エチニル]メトキシホスフィニ
ル]−3−ヒドロキシブタン酸またはそのメチルエステ
ル;(5Z)−4−[[2−[4'−フルオロ−3,3',5−ト
リメチル−[1,1'−ビフェニル]−2−イル]エテニル]
ヒドロキシホスフィニル]−3−ヒドロキシブタン酸ま
たはそのメチルエステル;(S)−4−[[2−[3−(4−
フルオロフェニル)−1−(1−メチルエチル)−1H−
インドール−2−イル]エチル]メトキシホスフィニル]
−3−ヒドロキシブタン酸メチルエステル;(S)−4−
[[2−[[1,1'−ビフェニル]−2−イル]エチル]メト
キシホスフィニル]−3−ヒドロキシブタン酸メチルエ
ステル;(S)−4−[[2−[4'−フルオロ−3,3',5−
トリメチル−[1,1'−ビフェニル]−2−イル]エチル]
ヒドロキシホスフィニル]−3−ヒドロキシブタン酸ジ
リチウム塩;(S)−4−[[2−[4'−フルオロ−3,3',
5−トリメチル−[1,1'−ビフェニル]−2−イル]エ
チニル]ヒドロキシホスフィニル]−3−ヒドロキシブタ
ン酸ジリチウム塩;(SZ)−4−[[2−[4'−フルオロ
−3,3',5−トリメチル−[1,1'−ビフェニル]−2
−イル]エテニル]ヒドロキシホスフィニル]−3−ヒド
ロキシブタン酸ジリチウム塩;(S)−4−[[2−[3−
(4−フルオロフェニル)−1−(1−メチルエチル)−1
H−インドール−2−イル]エチル]ヒドロキシホスフィ
ニル]−3−ヒドロキシブタン酸ジリチウム塩;(S)−4
−[[2−[[1,1'−ビフェニル]−2−イル]エチル]ヒ
ドロキシホスフィニル]−3−ブタン酸ジリチウム塩;
(S)−4−(ヒドロキシメトキシホスフィニル)−3−
[[(1,1−ジメチルエチル)ジフェニルシリル]オキシ]
ブタン酸メチルエステルまたはそのジシクロヘキシルア
ミン(1:1)塩;(S)−4−[[2−[1−(4−フルオロ
フェニル)−3−(1−メチルエチル)−1−インドール
−2−イル]エチニル]ヒドロキシホスフィニル]−3−
ヒドロキシブタン酸またはそのジリチウムもしくはジナ
トリウム塩あるいはメチルエステル;(E)−4−[[2−
[3−(4−フルオロフェニル−1−(1−メチルエチル)
−1H−インドール−2−イル]エテニル]ヒドロキシホ
スフィニル]−3−ヒドロキシブタン酸またはそのジリ
チウム塩あるいはメチルエステル;4−[[2−[4'−フ
ルオロ−3,3',5−トリメチル[1,1'−ビフェニル]
−2−イル]エチル]ヒドロキシホスフィニル]−3−ヒ
ドロキシブタン酸またはそのジリチウム塩あるいはメチ
ルエステル;(E)−4−[[2−[4'−フルオロ−3,3',
5−トリメチル[1,1'−ビフェニル]−2−イル]エテ
ニル]ヒドロキシホスフィニル]−3−ヒドロキシブタン
酸またはそのジリチウム塩あるいはメチルエステル;
(S)−4−[[[2,4−ジメチル−6−[(4−フルオロフ
ェニル)メトキシ]フェニル]エチル]ヒドロキシホスフィ
ニル]−3−ヒドロキシブタン酸またはそのジリチウム
塩あるいはメチルエステル;(S)−4−[[[2,4−ジメ
チル−6−[(4−フルオロフェニル)メトキシ]フェニ
ル]エチニル]ヒドロキシホスフィニル]−3−ヒドロキ
シブタン酸またはそのジリチウム塩あるいはメチルエス
テル;(S)−4−[[2−[3,5−ジメチル[1,1'−ビフ
ェニル]−2−イル]エチル]ヒドロキシホスフィニル]−
3−ヒドロキシブタン酸またはそのジリチウム塩あるい
はメチルエステル;(S)−4−[[2−[4'−フルオロ−
3,5−ジメチル[1,1'−ビフェニル]−2−イル]エチ
ル]ヒドロキシホスフィニル]−3−ヒドロキシブタン酸
またはそのジリチウム塩あるいはメチルエステル;(S)
−4−[[2−[[1,1'−ビフェニル]−2−イル]エチニ
ル]ヒドロキシホスフィニル]−3−ヒドロキシブタン酸
またはそのジリチウム塩あるいはメチルエステル;(S)
−4−[[2−(5−(4−フルオロフェニル)−3−(1−
メチルエチル)−1−フェニル−1H−ピラゾール−4
−イル]エチニル]メトキシホスフィニル]−3−ヒドロ
キシブタン酸メチルエステル;(S)−4−[[2−[1−
(4−フルオロフェニル)−3−(1−メチルエチル)−1
H−インドール−2−イル]エチル]ヒドロキシホスフィ
ニル]−3−ヒドロキシブタン酸またはそのジリチウム
塩あるいはメチルエステル;(S)−4−[[2−[5−(4
−フルオロフェニル)−3−(1−メチルエチル)−1−
フェニル−1H−ピラゾール−4−イル]エチニル]ヒド
ロキシホスフィニル]−3−ヒドロキシブタン酸ジリチ
ウム塩;(E)−4−[[2−[5−(4−フルオロフェニル)
−3−(1−メチルエチル)−1−フェニル−1H−ピラ
ゾール−4−イル]エテニル]メトキシホスフィニル]−
3−ヒドロキシブタン酸メチルエステル;(E)−4−
[[2−[5−(4−フルオロフェニル)−3−(1−メチル
エチル)−1−フェニル−1H−ピラゾール−4−イル]
エテニル]ヒドロキシホスフィニル]−3−ヒドロキシブ
タン酸ジリチウム塩;(S)−4−[[2−[5−(4−フル
オロフェニル)−3−(1−メチルエチル)−1−フェニ
ル−1H−ピラゾール−4−イル]エチル]メトキシホス
フィニル]−3−ヒドロキシブタン酸メチルエステル;
(S)−4−[[2−[5−(4−フルオロフェニル)−3−
(1−メチルエチル)−1−フェニル−1H−ピラゾール
−4−イル]エチル]ヒドロキシホスフィニル]−3−ヒ
ドロキシブタン酸ジリチウム塩;(S)−4−[[2−[3−
(4−フルオロフェニル)−5−(1−メチルエチル)−1
−フェニル−1H−ピラゾール−4−イル]エチル]メト
キシホスフィニル]−3−ヒドロキシブタン酸メチルエ
ステル;(S)−4−[[2−[3−(4−フルオロフェニル)
−5−(1−メチルエチル)−1−フェニル−1H−ピラ
ゾール−4−イル]エチル]ヒドロキシホスフィニル]−
3−ヒドロキシブタン酸ジリチウム塩;(S)−4−[[2
−[3−(4−フルオロフェニル)−5−(1−メチルエチ
ル)−1−フェニル−1H−ピラゾール−4−イル]エチ
ニル]メトキシホスフィニル]−3−ヒドロキシブタン
酸メチルエステル;(S)−4−[[2−[3−(4−フル
オロフェニル)−5−(1−メチルエチル)−1−フェニ
ル−1H−ピラゾール−4−イル]エチニル]ヒドロキシ
ホスフィニル]−3−ヒドロキシブタン酸ジリチウム塩;
(S)−4−[[[4−(4−フルオロフェニル)−1−(1−
メチルエチル)−3−フェニル−1H−ピラゾール−5
−イル]エチニル]メトキシホスフィニル]−3−ヒドロ
キシブタン酸メチルエステル;(S)−4−[[[4−(4−
フルオロフェニル)−1−(1−メチルエチル)−3−フ
ェニル−1H−ピラゾール−5−イル]エチニル]ヒドロ
キシホスフィニル]−3−ヒドロキシブタン酸ジリチウ
ム塩;(S)−4−[[2−[4−(4−フルオロフェニル)−
1−(1−メチルエチル)−3−フェニル−1H−ピラゾ
ール−5−イル]エチル]メトキシホスフィニル]−3−
ヒドロキシブタン酸メチルエステル;(S)−4−[[2−
[4−(4−フルオロフェニル)−1−(1−メチルエチ
ル)−3−フェニル−1H−ピラゾール−5−イル]エチ
ル]ヒドロキシホスフィニル]−3−ヒドロキシブタン酸
ジリチウム塩;(S)−4−[[[1−(4−フルオロフェニ
ル)−4−(1−メチルエチル)−2−フェニル−1H−
イミダゾール−5−イル]エチニル]メトキシホスフィニ
ル]−3−ヒドロキシブタン酸メチルエステル;(S)−4
−[[[1−(4−フルオロフェニル)−4−(1−メチルエ
チル)−2−フェニル−1H−イミダゾール−5−イル]
エチニル]メトキシホスフィニル]−3−ヒドロキシブタ
ン酸メチルエステル;(S)−4−[[2−[1−(4−フル
オロフェニル)−4−(1−メチルエチル)−2−フェニ
ル−1H−イミダゾール−5−イル]エチル]メトキシホ
スフィニル]−3−ヒドロキシブタン酸メチルエステル;
(S)−4−[[2−[1−(4−フルオロフェニル)−4−
(1−メチルエチル)−2−フェニル−1H−イミダゾー
ル−5−イル]エチル]ヒドロキシホスフィニル]−3−
ヒドロキシブタン酸ジリチウム塩;(S)−4−[[[2−
(シクロヘキシルメチル)−4,6−ジメチルフェニル]エ
チニル]ヒドロキシホスフィニル]−3−ヒドロキシブタ
ン酸またはそのジリチウム塩あるいはメチルエステル;
4−[[2−[2−(シクロヘキシルメチル)−4,6−ジメ
チルフェニル]エテニル]ヒドロキシホスフィニル]−3
−ヒドロキシブタン酸またはそのジリチウム塩あるいは
メチルエステル;(S)−4−[[2−[2−(シクロヘキシ
ルメチル)−4,6−ジメチルフェニル]エチル]ヒドロキ
シホスフィニル]−3−ヒドロキシブタン酸またはその
ジリチウム塩あるいはメチルエステル;4−[[[[4'−フ
ルオロ−3,3',5−トリメチル[1,1'−ビフェニル]
−2−イル]オキシ]メチル]ヒドロキシホスフィニル]−
3−ヒドロキシブタン酸またはそのジリチウム塩あるい
はメチルエステル;4−[[[4'−フルオロ−3,3',5−
トリメチル[1,1'−ビフェニル]−2−イル]メチル]ヒ
ドロキシホスフィニル]−3−ヒドロキシブタン酸また
はそのジリチウム塩あるいはメチルエステル;(S)−4
−[[[1−(4−フルオロフェニル)−3−メチル−2−
ナフタレニル]エチニル]ヒドロキシホスフィニル]−3
−ヒドロキシブタン酸またはそのジリチウム塩あるいは
メチルエステル;(E)−4−[[2−[1−(4−フルオロ
フェニル)−3−メチル−2−ナフタレニル]エテニル]
ヒドロキシホスフィニル]−3−ヒドロキシブタン酸ま
たはそのジリチウム塩あるいはメチルエステル;(S)−
4−[[2−[1−(4−フルオロフェニル)−3−メチル
−2−ナフタレニル]エチル]ヒドロキシホスフィニル]
−3−ヒドロキシブタン酸またはそのジリチウム塩ある
いはメチルエステル;4−[[3−[4'−フルオロ−3,
3',5−トリメチル[1,1'−ビフェニル]−2−イル]
プロピル]メトキシホスフィニル]−3−ヒドロキシブタ
ン酸メチルエステル;4−[[3−[4'−フルオロ−3,
3',5−トリメチル[1,1'−ビフェニル]−2−イル]
プロピル]ヒドロキシホスフィニル]−3−ヒドロキシブ
タン酸ジリチウム塩;[1S−[1α(R*),2α,4αβ,
8β,8aα]]−4−[[2−[8−(2,2−ジメチル−1
−オキソブトキシ)デカヒドロ−2−メチル−1−ナフ
タレニル]エチル]メトキシホスフィニル]−3−ヒドロ
キシブタン酸メチルエステル;[1S−[1α(R*),2
α,4aβ,8β,8aβ]]−4−[[2−[8−(2,2−ジ
メチル−1−オキソブトキシ)デカヒドロ−2−メチル
−1−ナフタレニル]エチル]ヒドロキシホスフィニル]
−3−ヒドロキシブタン酸ジリチウム塩;(S)−4−
[[[3'−(4−フルオロフェニル)スピロ]シクロペンタ
ン−1,1'−[1H]インデン]−2−イル]エチニル]メ
トキシホスフィニル]−3−ヒドロキシブタン酸メチル
エステル;および(S)−4−[[[3'−(4−フルオロフェ
ニル)スピロ]シクロペンタン−1,1'−[1H]インデ
ン]−2−イル]エチニル]ヒドロキシホスフィニル]−3
−ヒドロキシブタン酸ジリチウム塩が包含される。好ま
しいのはプラバスタチンまたはSQ33600である。Specific examples of such compounds include (S) -4
-[[[1- (4-Fluorophenyl) -3- (1-methylethyl) -1H-indol-2-yl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its sodium salt (SQ33600) (This is preferable) or dilithium salt; (S) -4-[[(E) -2- [4'-fluoro-3,3 ', 5-trimethyl- [1,1'-biphenyl]
-2-yl] ethenyl] hydroxyphosphinyl] -3-
Hydroxybutanoic acid or its dilithium salt; (S) -4
-[[2- [4'-fluoro-3,3 ', 5-trimethyl-
[1,1'-Biphenyl] -2-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid methyl ester or its mono- or dialkali metal salt; (S) -4-
[[[4'-Fluoro-3,3 ', 5-trimethyl- [1,1'-
Biphenyl] -2-yl] ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid or its methyl ester; (5Z) -4-[[2- [4'-fluoro-3,3 ', 5-trimethyl- [1,1'-Biphenyl] -2-yl] ethenyl]
Hydroxyphosphinyl] -3-hydroxybutanoic acid or its methyl ester; (S) -4-[[2- [3- (4-
Fluorophenyl) -1- (1-methylethyl) -1H-
Indole-2-yl] ethyl] methoxyphosphinyl]
-3-Hydroxybutanoic acid methyl ester; (S) -4-
[[2-[[1,1'-Biphenyl] -2-yl] ethyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S) -4-[[2- [4'-fluoro- 3,3 ', 5-
Trimethyl- [1,1'-biphenyl] -2-yl] ethyl]
Hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4-[[2- [4'-fluoro-3,3 ',
5-Trimethyl- [1,1'-biphenyl] -2-yl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (SZ) -4-[[2- [4'-fluoro-3 , 3 ', 5-Trimethyl- [1,1'-biphenyl] -2
-Yl] ethenyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4-[[2- [3-
(4-fluorophenyl) -1- (1-methylethyl) -1
H-indol-2-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4
-[[2-[[1,1'-biphenyl] -2-yl] ethyl] hydroxyphosphinyl] -3-butanoic acid dilithium salt;
(S) -4- (Hydroxymethoxyphosphinyl) -3-
[[(1,1-Dimethylethyl) diphenylsilyl] oxy]
Butanoic acid methyl ester or its dicyclohexylamine (1: 1) salt; (S) -4-[[2- [1- (4-fluorophenyl) -3- (1-methylethyl) -1-indole-2- Ill] ethynyl] hydroxyphosphinyl] -3-
Hydroxybutanoic acid or its dilithium or disodium salt or methyl ester; (E) -4-[[2-
[3- (4-fluorophenyl-1- (1-methylethyl)
-1H-Indol-2-yl] ethenyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; 4-[[2- [4'-fluoro-3,3 ', 5-trimethyl] [1,1'-biphenyl]
-2-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (E) -4-[[2- [4'-fluoro-3,3 ',
5-trimethyl [1,1'-biphenyl] -2-yl] ethenyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester;
(S) -4-[[[2,4-Dimethyl-6-[(4-fluorophenyl) methoxy] phenyl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; S) -4-[[[2,4-Dimethyl-6-[(4-fluorophenyl) methoxy] phenyl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (S ) -4-[[2- [3,5-Dimethyl [1,1'-biphenyl] -2-yl] ethyl] hydroxyphosphinyl]-
3-Hydroxybutanoic acid or its dilithium salt or methyl ester; (S) -4-[[2- [4'-fluoro-
3,5-Dimethyl [1,1'-biphenyl] -2-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (S)
-4-[[2-[[1,1'-biphenyl] -2-yl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (S)
-4-[[2- (5- (4-fluorophenyl) -3- (1-
Methylethyl) -1-phenyl-1H-pyrazole-4
-Yl] ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S) -4-[[2- [1-
(4-fluorophenyl) -3- (1-methylethyl) -1
H-indol-2-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (S) -4-[[2- [5- (4
-Fluorophenyl) -3- (1-methylethyl) -1-
Phenyl-1H-pyrazol-4-yl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (E) -4-[[2- [5- (4-fluorophenyl)
-3- (1-Methylethyl) -1-phenyl-1H-pyrazol-4-yl] ethenyl] methoxyphosphinyl]-
3-Hydroxybutanoic acid methyl ester; (E) -4-
[[2- [5- (4-Fluorophenyl) -3- (1-methylethyl) -1-phenyl-1H-pyrazol-4-yl]
Ethenyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4-[[2- [5- (4-fluorophenyl) -3- (1-methylethyl) -1-phenyl-1H -Pyrazol-4-yl] ethyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester;
(S) -4-[[2- [5- (4-fluorophenyl) -3-
(1-Methylethyl) -1-phenyl-1H-pyrazol-4-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4-[[2- [3-
(4-fluorophenyl) -5- (1-methylethyl) -1
-Phenyl-1H-pyrazol-4-yl] ethyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S) -4-[[2- [3- (4-fluorophenyl)
-5- (1-Methylethyl) -1-phenyl-1H-pyrazol-4-yl] ethyl] hydroxyphosphinyl]-
3-Hydroxybutanoic acid dilithium salt; (S) -4-[[2
-[3- (4-Fluorophenyl) -5- (1-methylethyl) -1-phenyl-1H-pyrazol-4-yl] ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S ) -4-[[2- [3- (4-Fluorophenyl) -5- (1-methylethyl) -1-phenyl-1H-pyrazol-4-yl] ethynyl] hydroxyphosphinyl] -3-hydroxy Butyric acid dilithium salt;
(S) -4-[[[4- (4-fluorophenyl) -1- (1-
Methylethyl) -3-phenyl-1H-pyrazole-5
-Yl] ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S) -4-[[[4- (4-
Fluorophenyl) -1- (1-methylethyl) -3-phenyl-1H-pyrazol-5-yl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4-[[2 -[4- (4-fluorophenyl)-
1- (1-methylethyl) -3-phenyl-1H-pyrazol-5-yl] ethyl] methoxyphosphinyl] -3-
Hydroxybutanoic acid methyl ester; (S) -4-[[2-
[4- (4-Fluorophenyl) -1- (1-methylethyl) -3-phenyl-1H-pyrazol-5-yl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; (S) -4-[[[1- (4-fluorophenyl) -4- (1-methylethyl) -2-phenyl-1H-
Imidazol-5-yl] ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S) -4
-[[[1- (4-Fluorophenyl) -4- (1-methylethyl) -2-phenyl-1H-imidazol-5-yl]
Ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; (S) -4-[[2- [1- (4-fluorophenyl) -4- (1-methylethyl) -2-phenyl-1H -Imidazol-5-yl] ethyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester;
(S) -4-[[2- [1- (4-fluorophenyl) -4-
(1-Methylethyl) -2-phenyl-1H-imidazol-5-yl] ethyl] hydroxyphosphinyl] -3-
Hydroxybutanoic acid dilithium salt; (S) -4-[[[[2-
(Cyclohexylmethyl) -4,6-dimethylphenyl] ethynyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester;
4-[[2- [2- (cyclohexylmethyl) -4,6-dimethylphenyl] ethenyl] hydroxyphosphinyl] -3
-Hydroxybutanoic acid or its dilithium salt or methyl ester; (S) -4-[[2- [2- (cyclohexylmethyl) -4,6-dimethylphenyl] ethyl] hydroxyphosphinyl] -3-hydroxybutanoic acid Or its dilithium salt or methyl ester; 4-[[[[4'-fluoro-3,3 ', 5-trimethyl [1,1'-biphenyl]
-2-yl] oxy] methyl] hydroxyphosphinyl]-
3-hydroxybutanoic acid or its dilithium salt or methyl ester; 4-[[[4'-fluoro-3,3 ', 5-
Trimethyl [1,1'-biphenyl] -2-yl] methyl] hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (S) -4
-[[[1- (4-Fluorophenyl) -3-methyl-2-
Naphthalenyl] ethynyl] hydroxyphosphinyl] -3
-Hydroxybutanoic acid or its dilithium salt or methyl ester; (E) -4-[[2- [1- (4-fluorophenyl) -3-methyl-2-naphthalenyl] ethenyl]
Hydroxyphosphinyl] -3-hydroxybutanoic acid or its dilithium salt or methyl ester; (S)-
4-[[2- [1- (4-fluorophenyl) -3-methyl-2-naphthalenyl] ethyl] hydroxyphosphinyl]
-3-hydroxybutanoic acid or its dilithium salt or methyl ester; 4-[[3- [4'-fluoro-3,
3 ', 5-trimethyl [1,1'-biphenyl] -2-yl]
Propyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; 4-[[3- [4'-fluoro-3,
3 ', 5-trimethyl [1,1'-biphenyl] -2-yl]
Propyl] hydroxyphosphinyl] -3-hydroxybutanoic acid dilithium salt; [1S- [1α (R *), 2α, 4αβ,
8β, 8aα]]-4-[[2- [8- (2,2-dimethyl-1
-Oxobutoxy) decahydro-2-methyl-1-naphthalenyl] ethyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; [1S- [1α (R *), 2
α, 4aβ, 8β, 8aβ]]-4-[[2- [8- (2,2-Dimethyl-1-oxobutoxy) decahydro-2-methyl-1-naphthalenyl] ethyl] hydroxyphosphinyl]
-3-Hydroxybutanoic acid dilithium salt; (S) -4-
[[[3 '-(4-Fluorophenyl) spiro] cyclopentane-1,1'-[1H] inden] -2-yl] ethynyl] methoxyphosphinyl] -3-hydroxybutanoic acid methyl ester; and ( S) -4-[[[3 '-(4-Fluorophenyl) spiro] cyclopentane-1,1'-[1H] inden] -2-yl] ethynyl] hydroxyphosphinyl] -3
-Hydroxybutanoic acid dilithium salt is included. Preferred is pravastatin or SQ33600.
【0010】本発明で使用しうるACE抑制剤として
は、好ましくは、メルカプト(−S−)成分を含有するも
の、たとえば上記オンデッティらのU.S.特許No.4
046889に開示されているような置換プロリン誘導
体が包含され、この中でカプトプリル、すなわち、1−
[(2S)−3−メルカプト−2−メチルプロピオニル]−
L−プロリンが好ましく、またU.S.特許No.431
6906に開示されているような置換プロリン類のメル
カプトアシル誘導体も包含され、この中でゾフェノプリ
ルが好ましい。The ACE inhibitor which can be used in the present invention is preferably one containing a mercapto (--S--) component, such as the above-mentioned US Pat. No. 4 of Ondetti et al.
Substituted proline derivatives as disclosed in 046889, including captopril, ie 1-
[(2S) -3-Mercapto-2-methylpropionyl]-
L-proline is preferred and US Pat. No. 431
Also included are mercaptoacyl derivatives of substituted prolines as disclosed in 6906, of which zofenopril is preferred.
【0011】本発明で使用しうるメルカプト含有ACE
抑制剤の他の具体例としては、「Clin.Exp.Pharmac
ol.Physiol.」(10:131、1983年)に開示のレ
ンチアプリル(フェンチアプリル、サンテン);並びに
式:Mercapto-containing ACE that can be used in the present invention
Other specific examples of the inhibitor include "Clin. Exp. Pharmac.
ol. Physiol. "(10: 131, 1983), lentiapril (fentiapril, Santeng); and formula:
【化3】 のピボプリル、および式:Embedded image Pivopril, and the formula:
【化4】 のYS980が包含される。[Chemical 4] No. YS980 is included.
【0012】本発明で使用しうるACE抑制剤の他の具
体例としては、上記U.S.特許No.4374829に
開示のもの[N−(1−エトキシカルボニル−3−フェニ
ルプロピル)−L−アラニル−L−プロリン、すなわ
ち、エナラプリルが好ましい];U.S.特許No.445
2790に開示のホスホネート置換アミノ酸もしくはイ
ミノ酸またはこれらの塩[(S)−1−[6−アミノ−2−
[[ヒドロキシ−(4−フェニルブチル)ホスフィニル]オ
キシ]−1−オキソヘキシル]−L−プロリン(SQ29
852またはセラナプリル)が好ましい];上記U.S.特
許No.4168267に開示のホスフィニルアルカノ
イルプロリン類[ホシノプリルが好ましい];U.S.特許
No.4337201に開示のホスフィニルアルカノイ
ル置換プロリン類;および上記U.S.特許No.4432
971に開示のホスホンアミデート類が包含される。Other specific examples of the ACE inhibitor usable in the present invention include those disclosed in the above-mentioned US Pat. No. 4374829 [N- (1-ethoxycarbonyl-3-phenylpropyl) -L- Alanyl-L-proline, ie enalapril, is preferred]; US Patent No. 445
2790 discloses phosphonate-substituted amino acids or imino acids or salts thereof [(S) -1- [6-amino-2-
[[Hydroxy- (4-phenylbutyl) phosphinyl] oxy] -1-oxohexyl] -L-proline (SQ29
852 or seranapril)]; phosphinylalkanoylprolines disclosed in US Pat. No. 4,168,267 above [phosinopril is preferred]; phosphinylalkanoyl-substituted prolines disclosed in US Pat. No. 4337201. And the above-mentioned US Patent No. 4432
The phosphonamidates disclosed in 971 are included.
【0013】本発明で使用しうるACE抑制剤の他の具
体例としては、ヨーロッパ特許No.80822および
60668に開示のビーチャム(Beecham)のBRL36
378;「CA.」(102:72588v)および「Jap.
J.Pharmacol」(40:373、1986年)に開示のチ
ューガイ(Chugai)のMC−838;U.K.特許No.2
103614に開示のチバ−ガイギィー(Ciba−Geig
y)のCGS14824[すなわち、3−([1−エトキシ
カルボニル−3−フェニル−(1S)−プロピル]アミノ)
−2,3,4,5−テトラヒドロ−2−オキソ−1−(3
S)−ベンズアゼピン−1−酢酸・HCl]およびU.S.
特許No.4473575に開示のCGS16617[す
なわち、3(S)−[[(1S)−5−アミノ−1−カルボキ
シペンチル]アミノ]−2,3,4,5−テトラヒドロ−2
−オキソ−1H−1−ベンズアゼピン−1−エタン酸];
「Eur.Therap.Res.」(39:671、1986
年),(40:543、1986年)に開示のセタプリル
(アラセプリル、ダイニッポン);ヨーロッパ特許No.7
9−022および「Curr.Ther.Res.」(40:74、
1986年)に開示のラミプリル(ヘキスト);「Arzneimi
ttel−forschung」(35:1254、1985年)に開示
のRu44570(ヘキスト)、「J.Cardiovasc.
Pharmacol.」(9:39、1987年)に開示のシラザプ
リル(ホフマン−ラ・ロッシュ);「FEBS Lett.」(1
65:201、1984年)に開示のRo31−2201
(ホフマン−ラ・ロッシュ);「Curr.Therap.Res.」
(37:342、1985年)およびヨーロッパ特許出願
No.12−401に開示のリシノプリル(メルク)、U.
S.特許No.4385051に開示のインダラプリル
(デラプリル);「J.Cardiovasc.Pharmacol.」(5:6
43、655、1983年)に開示のインドラプリル(シ
ェリング);「Acta.Pharmacol.Toxicol.」(59(Sup
p.5):173、1986年)に開示のスピラプリル(シ
ェリング);「Eur.J.Clin.Pharmacol.」(31:51
9、1987年)に開示のペリンドプリル(サービア);
U.S.特許No.4344949に開示のキナプリル(ワ
ーナー−ランバート)、「Pharmacologist」(26:24
3、266、1984年)に開示のCI925(ワーナー
ランバート)[すなわち、[3S−[2−[R(*),R(*)]]
3R(*)]−2−[2−[[1−(エトキシカルボニル)−3
−フェニルプロピル]アミノ]−1−オキソプロピル]−
1,2,3,4−テトラヒドロ−6,7−ジメトキシ−3−
イソキノリンカルボン酸HCl]、「J.Med.Che
m.」(26:394、1983年)に開示のWY−44
221(ワイース)が包含される。Other specific examples of ACE inhibitors which may be used in the present invention include Beecham BRL 36 disclosed in European Patent Nos. 80822 and 60668.
378; "CA." (102: 72588v) and "Jap.
J. Pharmacol "(40: 373, 1986), Chugai MC-838; UK Patent No. 2;
No. 103614, Ciba-Geig
y) CGS 14824 [ie 3-([1-ethoxycarbonyl-3-phenyl- (1S) -propyl] amino)
-2,3,4,5-tetrahydro-2-oxo-1- (3
S) -Benzazepine-1-acetic acid.HCl] and USS.
CGS 16617 [namely, 3 (S)-[[(1S) -5-amino-1-carboxypentyl] amino] -2,3,4,5-tetrahydro-2 disclosed in Patent No. 4473575.
-Oxo-1H-1-benzazepine-1-ethanoic acid];
"Eur. Therap. Res." (39: 671, 1986).
,) (40: 543, 1986)
(Arasepril, Nippon); European Patent No. 7
9-022 and "Curr. Ther. Res." (40:74,
1986) Ramipril (Hoechst); "Arzneimi
“Ttel-forschung” (35: 1254, 1985), Ru44570 (Hoechst), “J. Cardiovasc.
Pharmacol. "(9:39, 1987) Cilazapril (Hoffmann-La Roche);" FEBS Lett. "(1
65: 201, 1984) disclosed in Ro 31-2201.
(Hoffman-La Roche); "Curr. Therap. Res."
(37: 342, 1985) and European Patent Application No. 12-401, Lisinopril (Merck), U.S. Pat.
Indarapril disclosed in S. Patent No. 4385051
(Delapril); "J. Cardiovasc. Pharmacol." (5: 6
43, 655, 1983) disclosed Indrapril (Schering); "Acta. Pharmacol. Toxicol." (59 (Sup
p. 5): 173, 1986) disclosed Spirapril (Schering); "Eur. J. Clin. Pharmacol." (31:51).
9, 1987) disclosed by Perindopril (Serbia);
Kinapril (Warner-Lambert), disclosed in US Pat. No. 4,344,949, “Pharmacologist” (26:24.
3, 266, 1984) CI 925 (Warner Lambert) [ie, [3S- [2- [R (*), R (*)]].
3R (*)]-2- [2-[[1- (ethoxycarbonyl) -3
-Phenylpropyl] amino] -1-oxopropyl]-
1,2,3,4-tetrahydro-6,7-dimethoxy-3-
Isoquinolinecarboxylic acid HCl], “J. Med. Che
m. (26: 394, 1983).
221 (Wyeth) is included.
【0014】好ましいACE抑制剤は、プロリンまたは
置換プロリン誘導体であって、メルカプト基を包含する
ACE抑制剤といったものが最も好ましい。Preferred ACE inhibitors are proline or substituted proline derivatives, most preferably ACE inhibitors containing a mercapto group.
【0015】本発明の治療実施に際し、HMG CoA
レダクターゼ抑制剤を単独またはACE抑制剤と組合せ
て、実質的正常な血清コレステロール量を持つ哺乳動
物、たとえばイヌ、ネコ、ヒト等に対し投与することが
でき、かつ該HMG CoAレダクターゼ抑制剤を通常
の全身系投与剤形で、たとえば錠剤、カプセル剤、エリ
キシル剤または注射液に混和しうる。かかる投与剤形に
は、必要な担体物質、賦形剤、潤滑剤、緩衝剤、抗菌
剤、増量剤(たとえばマンニトール)、酸化防止剤(アス
コルビン酸または重亜硫酸ナトリウム)等を含ませても
よい。経口投与剤形が好ましいが、非経口投与剤形も同
様に十分満足な結果が得られる。In carrying out the treatment of the present invention, HMG CoA
The reductase inhibitor alone or in combination with the ACE inhibitor can be administered to mammals having substantially normal serum cholesterol levels, such as dogs, cats, humans, etc., and the HMG CoA reductase inhibitor It may be incorporated in systemic dosage form, for example in tablets, capsules, elixirs or injectable solutions. Such dosage forms may contain necessary carrier substances, excipients, lubricants, buffers, antibacterial agents, bulking agents (eg mannitol), antioxidants (ascorbic acid or sodium bisulfite) and the like. . Oral dosage forms are preferred, but parenteral dosage forms likewise give satisfactory results.
【0016】投与量は、患者の年令、体重および症状、
並びに投与法、投与剤形や生活規則および所望結果に従
って注意深く調整しなければならない。すなわち、経口
投与の場合、HMG CoAレダクターゼ抑制剤を採用
される投与量で、たとえば、「the Physician's Desk
Reference」に示されるように、プラバスタチン、ロバ
スタチンおよびシンバスタチンでは、約1〜2000m
g、好ましくは約4〜200mg範囲内の量で使用する
ことにより、満足な結果が得られる。The dose depends on the age, weight and symptoms of the patient,
It must be carefully adjusted according to the dosing regimen, dosage form, lifestyle rules and desired result. That is, in the case of oral administration, the dose of the HMG CoA reductase inhibitor used is, for example, "the Physician's Desk".
As shown in "Reference", pravastatin, lovastatin and simvastatin have about 1 to 2000 m.
Satisfactory results are obtained by using g, preferably in an amount in the range of about 4-200 mg.
【0017】好ましい経口投与剤形、たとえば錠剤また
はカプセル剤は、HMG CoAレダクターゼ抑制剤を
約0.5〜100mg、好ましくは約5〜80mg、よ
り好ましくは約10〜40mgの量で含有するだろう。
ACE抑制剤については、ACE抑制剤を約0.01〜
100mg/kg、好ましくは約0.1〜5mg/kg
範囲内の量で用いることにより、満足な結果が得られ
る。Preferred oral dosage forms, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount of about 0.5-100 mg, preferably about 5-80 mg, more preferably about 10-40 mg. .
As for the ACE inhibitor, the ACE inhibitor is about 0.01-
100 mg / kg, preferably about 0.1-5 mg / kg
When used in an amount within the range, satisfactory results are obtained.
【0018】好ましい経口投与剤形、たとえば錠剤また
はカプセル剤は、ACE抑制剤を約0.1〜500m
g、好ましくは約2〜50mgの量で含有するだろう。
非経口投与の場合、ACE抑制剤は約0.005〜10
mg/kg、好ましくは約0.005〜2mg/kg範
囲内の量で用いられるだろう。HMG CoAレダクタ
ーゼ抑制剤とACE抑制剤は、同一の経口投与剤形に一
緒に使用してもよく、あるいは別々の経口投与剤形で用
いられ、これらを同時に投与してもよい。A preferred oral dosage form, such as a tablet or capsule, contains an ACE inhibitor in an amount of about 0.1-500 m.
g, preferably about 2-50 mg.
In the case of parenteral administration, the ACE inhibitor is about 0.005 to 10
mg / kg, preferably in an amount within the range of about 0.005 to 2 mg / kg. The HMG CoA reductase inhibitor and the ACE inhibitor may be used together in the same oral dosage form, or they may be used in separate oral dosage forms and they may be administered simultaneously.
【0019】かかるHMG CoAレダクターゼ抑制剤
単独または該抑制剤とACE抑制剤との組合せから成る
本発明組成物は、上述の投与剤形で1日当り1回用量ま
たは2〜4回の分割用量にて投与しうる。患者に対し最
初は低用量併用で開始し、徐々に高用量併用に増してい
くことが得策と思われる。種々の大きさの、たとえば総
重量約2〜2000mgの錠剤を製造することができ、
かかる錠剤は活性物質の一方または両方を上述の範囲量
で含有し、残りの成分は認定医薬実務による生理学的に
許容し得る担体あるいは他の物質である。これらの錠剤
は勿論、分別用量を付与する刻み目を付けることが出来
る。ゼラチンカプセル剤も同様に調剤しうる。The composition of the present invention comprising such an HMG CoA reductase inhibitor alone or a combination of the inhibitor and an ACE inhibitor is administered in the above-mentioned dosage form in a single dose or in 2 to 4 divided doses per day. Can be administered. It may be advisable to start with a low-dose combination for patients and gradually increase to a high-dose combination. It is possible to produce tablets of various sizes, for example with a total weight of about 2-2000 mg,
Such tablets contain one or both of the active substances in the above-recited amounts, with the remaining ingredients being physiologically acceptable carriers or other substances according to certified pharmaceutical practice. These tablets can, of course, be scored to give a discrete dose. Gelatin capsules can be prepared as well.
【0020】また液体製剤も、活性物質の1種または2
種以上の混合物を医薬投与に許容しうる通常の液体ビヒ
クルへ、茶さじ1〜4杯で所望の用量を付与できるよう
に溶解または懸濁することによって製造することができ
る。上述の本発明組成物は、上述の投与剤形で1日当り
1回用量または2〜4回の分割用量にて投与しうる。患
者に対し最初は低用量併用で開始し、徐々に高用量併用
に増して行くことが得策と思われる。Liquid formulations also include one or two of the active substances.
It may be prepared by dissolving or suspending the mixture of one or more in a conventional liquid vehicle that is acceptable for pharmaceutically administration and in a teaspoon of 1 to 4 so as to give the desired dose. The compositions of the invention described above may be administered in the dosage forms described above in a single dose or in 2-4 divided doses per day. It may be advisable to start with a low dose combination for the patient and gradually increase to a high dose combination.
【0021】かかる投与剤形は、患者に対し1日当り1
〜4回用量の生活規則で投与することができる、他の改
変によれば、用量スケジュールをより緻密に調整するた
め、活性物質をそれぞれ個々の投与単位にて分けて、同
時にまたは注意深く投与時間を調整して投与してもよ
い。投与の調整スケジュールによって、血液レベルが増
し維持されるので、2つの活性物質の同時存在によっ
て、同じ結果が得られる。それぞれの有効物質は、上述
と同様な方法で、別々の単位投与剤形にて個々に調製す
ることができる。Such a dosage form is 1 per day for a patient.
According to another modification, which can be administered in ~ 4 doses of life rules, the active substance is divided into each individual dosage unit, in order to adjust the dose schedule more precisely, with simultaneous or careful administration. You may adjust and administer. The co-presence of the two actives gives the same result, as the adjusted dosing schedule maintains and maintains blood levels. Each active substance can be individually prepared in separate unit dosage forms in a manner similar to that described above.
【0022】HMG CoAレダクターゼ抑制剤とAC
E抑制剤の固定した混合併用がより便宜であり、かつ特
に経口投与用の錠剤やカプセル剤の場合に好ましい。本
発明組成物の調剤において、上記量の活性物質を生理学
的に許容しうるビヒクル、担体、賦形剤、結合剤、保存
剤、安定化剤、フレーバー等と共に、認定医薬実務に従
って個々のタイプの単位投与剤形にて調合する。HMG CoA reductase inhibitor and AC
A fixed mixed combination of E inhibitors is more convenient and is preferred, especially in the case of tablets or capsules for oral administration. In the preparation of the composition of the present invention, the above-mentioned amount of the active substance together with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor and the like is prepared according to the approved pharmaceutical practice. Prepare in unit dosage form.
【0023】錠剤に混和しうる佐剤の具体例としては、
トラガカントゴム、アカシアゴム、コーンスターチまた
はゼラチンなどの結合剤;リン酸ジカルシウムまたはセ
ルロースなどの賦形剤;コーンスターチ、ポテトスター
チ、アルギン酸等などの崩壊剤;ステアリン酸またはス
テアリン酸マグネシウムなどの潤滑剤;スクロース、ア
スパルターメ(aspartame)、ラクトースまたはサッカリ
ンなどの甘味剤;オレンジ、ペパーミント、冬緑油また
はチェリーなどのフレーバーが挙げられる。単位投与剤
形がカプセル剤のとき、カプセル剤は上記種類の物質以
外に、脂肪油などの液体担体を含有してもよい。コーテ
ィング膜として、あるいはその他の投与単位の物理的形
状を改変するために、他の各種の物質が存在していても
よい。たとえば、錠剤またはカプセル剤をシェラックも
しくはシュガーまたは両方で被覆してもよい。シロップ
のエリキシル剤は、活性化合物、担体として水、アルコ
ール等、可溶化剤としてグリセロール、甘味剤としてス
クロース、保存剤としてメチルおよびプロピルパラベ
ン、染料およびフレーバー(たとえばチェリーまたはオ
レンジ)を含有しうる。Specific examples of adjuvants that can be mixed with tablets include:
Binders such as tragacanth gum, acacia gum, corn starch or gelatin; excipients such as dicalcium phosphate or cellulose; disintegrating agents such as corn starch, potato starch, alginic acid and the like; lubricants such as stearic acid or magnesium stearate; sucrose, Sweeteners such as aspartame, lactose or saccharin; flavors such as orange, peppermint, oil of wintergreen or cherry. When the unit dosage form is a capsule, the capsule may contain, in addition to materials of the above type, a liquid carrier such as fatty oil. Various other substances may be present as coatings or to modify the physical shape of other dosage units. For instance, tablets or capsules may be coated with shellac or sugar or both. A syrup elixir may contain the active compound, water as a carrier, alcohol and the like, glycerol as a solubilizer, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavor (eg cherry or orange).
【0024】上述の活性物質の幾つかは、一般に公知の
医薬的に許容しうる塩、たとえばアルカリ金属塩や他の
通常の塩基性塩あるいは酸付加塩等を形成する。従っ
て、ベース物質への言及は、親化合物と実質的に等価す
ることが知られているこれらの一般塩を含むことが意図
されている。上述の配合製剤は、長期間にわたって、す
なわち、二次心臓発作への可能性が残っているかあるい
はその症状が続く限り投与されるだろう。また、かかる
製剤にあって、所定量を2週間ごと、1週間ごと、1ケ
月ごとに付与しうる徐放性のものも使用しうる。最小限
度の薬効を得るには、少なくとも1〜2週間の投与期間
が必要である。Some of the above-mentioned active substances form generally known pharmaceutically acceptable salts, such as alkali metal salts and other usual basic salts or acid addition salts. Accordingly, reference to base materials are intended to include those common salts that are known to be substantially equivalent to the parent compound. The combination preparations described above will be administered for an extended period of time, ie as long as the potential for secondary heart attack remains or its symptoms persist. In addition, in such a preparation, a sustained-release preparation which can give a predetermined amount every two weeks, once a week, or once a month can be used. A dosing period of at least 1 to 2 weeks is required to obtain a minimal efficacy.
【0025】[0025]
【実施例】次に挙げる実施例は、本発明の好ましい具体
例を示すものである。 実施例1 下記組成を持つ錠剤形状のプラバスタチン製剤を、以下
の記載に従って製造した。 成分 重量部 プラバスタチン −−− 7 ラクトース −−− 67 微結晶セルロース −−− 20 クロスカルメロース(croscarmellose)ナトリウム・ −−− 2 ステアリン酸マグネシウム −−− 1 酸化マグネシウム −−− 3The following examples show preferred specific examples of the present invention. Example 1 A tablet-form pravastatin formulation having the following composition was prepared as described below. Ingredient parts by weight pravastatin ----- Lactose ----- 67 Microcrystalline cellulose ----- 20 Croscarmellose sodium ----- Magnesium stearate -1 Magnesium oxide -----
【0026】上記プラバスタチン、酸化マグネシウム、
およびラクトースの一部(30%)を共に、適当なミキサ
ーを用いて2〜10分間混合する。得られる混合物を、
#12〜#40メッシュサイズの篩に通す。微結晶セル
ロース、クロスカルメロース・ナトリウムおよび残りの
ラクトースを加え、混合物を2〜10分間混合する。そ
の後、ステアリン酸マグネシウムを加え、混合を1〜3
分間続ける。次いで、得られる均質混合物を、それぞれ
5mg、10mg、20mgまたは40mgのプラバス
タチン含有の錠剤に打錠する。これらの錠剤は、実質的
正常な血清コレステロール量を持つ患者の、二次心臓発
作の危険を予防または軽減するのに使用することができ
る。The above pravastatin, magnesium oxide,
And a portion of lactose (30%) together for 2-10 minutes using a suitable mixer. The resulting mixture is
Pass through a # 12- # 40 mesh size screen. Microcrystalline cellulose, croscarmellose sodium and the remaining lactose are added and the mixture is mixed for 2-10 minutes. Then add magnesium stearate and mix 1 to 3
Continue for a minute. The resulting homogeneous mixture is then compressed into tablets containing 5 mg, 10 mg, 20 mg or 40 mg pravastatin, respectively. These tablets can be used to prevent or reduce the risk of secondary heart attacks in patients with substantially normal serum cholesterol levels.
【0027】実施例2「 1990PDR」の記載に準じ、通常の医薬技法を用い
て、プラバスタチン20mgと、ロバスタチン錠剤で用
いられる不活性成分、すなわち、セルロース、着色剤、
ラクトース、ステアリン酸マグネシウムおよびスターチ
と、保存剤としてブチル化ヒドロキシアニソールとを含
有する、プラバスタチン錠剤を製造する。かかるプラバ
スタチン錠剤は、本発明に従って、実質的正常な血清コ
レステロール量を持つ患者の、二次心臓発作の危険を予
防または軽減するのに使用しうる。Example 2 According to the description of "1990PDR", 20 mg of pravastatin and the inactive ingredients used in the lovastatin tablet, ie, cellulose, a coloring agent, were prepared by the usual pharmaceutical technique.
Pravastatin tablets are prepared containing lactose, magnesium stearate and starch, and butylated hydroxyanisole as preservative. Such pravastatin tablets may be used according to the invention to prevent or reduce the risk of a secondary heart attack in patients with substantially normal serum cholesterol levels.
【0028】実施例3 下記組成の錠剤を、以下の記載に従って製造した。 成分 重量(mg) SQ33600 −−− 100 アビセル(Avicel) −−− 112.5 ラクトース −−− 113 コーンスターチ −−− 17.5 ステアリン酸 −−− 7 計 350 十分なバルク量から、上記SQ33600、アビセル、
およびステアリン酸の一部をスラグする(slugging)こと
により錠剤を製造する。スラグを粉砕し、#2篩に通
し、次いでラクトース、コーンスターチ、および残りの
ステアリン酸と一緒に混合する。混合物をタブレット成
形機にて、350mgカプセル型錠剤に打錠する。かか
る錠剤に半分に分ける刻み目を付ける。このようにして
形成される錠剤は、実質的正常な血清コレステロール量
を持つ患者の、二次心臓発作の危険を予防または軽減す
るため、本発明の技法に従って投与することができる。Example 3 Tablets of the following composition were made as described below. Ingredient weight (mg) SQ33600 --- 100 Avicel --- 112.5 Lactose --- 113 Corn starch --- 17.5 Stearic acid --- 7 Total 350 From the sufficient bulk amount, the above SQ33600, Avicel ,
And tablets are made by slugging a portion of the stearic acid. The slag is ground, passed through a # 2 sieve and then mixed with lactose, corn starch and the rest stearic acid. The mixture is tabletted on a tablet press into 350 mg capsule shaped tablets. The tablet is scored in half. The tablets thus formed can be administered according to the techniques of the present invention to prevent or reduce the risk of a secondary heart attack in patients with substantially normal serum cholesterol levels.
【0029】実施例4「 1990PDR」の記載に準じ、通常の医薬技法を用い
て、ロバスタチン20mg、セルロース、着色剤、ラク
トース、ステアリン酸マグネシウムおよびスターチと、
保存剤としてブチル化ヒドロキシアニソールとを含有す
る、ロバスタチン錠剤を製造する。かかるロバスタチン
錠剤は、本発明に従って、実質的正常な血清コレステロ
ール量を持つ患者の、二次心臓発作の危険を予防または
軽減するのに使用しうる。EXAMPLE 4 Lovastatin 20 mg, cellulose, colorant, lactose, magnesium stearate and starch, using conventional pharmaceutical techniques, as described in Example 4, "1990PDR".
Lovastatin tablets are prepared containing butylated hydroxyanisole as a preservative. Such lovastatin tablets may be used according to the invention to prevent or reduce the risk of a secondary heart attack in patients with substantially normal serum cholesterol levels.
【0030】実施例5 実施例1の記載に従って、錠剤形状のプラバスタチン製
剤を製造した。また、プラバスタチンと一緒に経口投与
するのに好適なカプトプリル製剤を、以下の記載に従っ
て製造した。それぞれ25mgの1−[(2S)−3−メ
ルカプト−2−メチルプロピオニル]−L−プロリン[カ
プトプリル]を含有する1000個の錠剤を下記成分か
ら製造する。 成分 g 1−[(2S)−3−メルカプト−2− メチルプロピオニル]−L−プロリン(カプトプリル) −−− 25 コーンスターチ −−− 50 ゼラチン −−− 7.5 アビセル(微結晶セルロース) −−− 25 ステアリン酸マグネシウム −−− 2.5Example 5 A pravastatin formulation in tablet form was prepared as described in Example 1. Also, a captopril formulation suitable for oral administration together with pravastatin was prepared as described below. 1000 tablets each containing 25 mg of 1-[(2S) -3-mercapto-2-methylpropionyl] -L-proline [captopril] are prepared from the following ingredients. Ingredient g 1-[(2S) -3-Mercapto-2-methylpropionyl] -L-proline (captopril) ----- 25 Corn starch ----- 50 Gelatin ----- 7.5 Avicel (microcrystalline cellulose) ----- 25 Magnesium stearate --- 2.5
【0031】上記カプトプリルおよびコーンスターチ
を、ゼラチンの水溶液と混合する。混合物を乾燥し、粉
砕して微粉末とする。アビセル、次いでステアリン酸マ
グネシウムを粗砕しながら混合する。次いで、これをタ
ブレット成形機にて打錠し、それぞれ25mgの活性成
分を含有する1000個の錠剤を形成する。かかるプラ
バスタチン錠剤とカプトプリル錠剤は、本発明の技法に
従って、実質的正常な血清コレステロール量を持つ患者
の、二次心臓発作の危険を予防または軽減するのに、併
用して投与しうる。加えて、これらのプラバスタチンお
よびカプトプリル錠剤を共に粉砕して粉末とし、1つの
カプセル内で使用してもよい。The above captopril and corn starch are mixed with an aqueous solution of gelatin. The mixture is dried and ground to a fine powder. Avicel and then magnesium stearate are mixed with the granulation. This is then tabletted on a tablet machine to form 1000 tablets, each containing 25 mg of active ingredient. Such pravastatin tablets and captopril tablets may be administered in combination according to the techniques of the present invention to prevent or reduce the risk of a secondary heart attack in patients with substantially normal serum cholesterol levels. In addition, these pravastatin and captopril tablets may be ground together into a powder and used in one capsule.
【0032】実施例6 実施例2の記載に従って、プラバスタチン錠剤を製造し
た。かかるプラバスタチン錠剤は、本発明に従って、実
質的正常な血清コレステロール量を持つ患者の、二次心
臓発作の危険を予防または軽減するため、エナラプリル
20mgおよび「1990 PDR」に記載の不活性成分
を含有するエナラプリル錠剤と併用して用いることがで
きる。Example 6 Pravastatin tablets were prepared as described in Example 2. Such pravastatin tablets contain, according to the invention, 20 mg enalapril and an inactive ingredient as described in the "1990 PDR" for the purpose of preventing or reducing the risk of secondary heart attacks in patients with substantially normal serum cholesterol levels. It can be used in combination with enalapril tablets.
【0033】実施例7 実施例3の記載に従って製造したSQ33600含有錠
剤は、実質的正常な血清コレステロール量を持つ患者
の、二次心臓発作の危険を予防または軽減するのに、2
5mgカプトプリル錠剤と一緒に投与しうる。Example 7 SQ33600-containing tablets prepared as described in Example 3 were used to prevent or reduce the risk of a secondary heart attack in patients with substantially normal serum cholesterol levels.
It may be co-administered with a 5 mg captopril tablet.
【0034】実施例8「 1990 PDR」の記載に準じ、通常の医薬技法を用
いて、ロバスタチン20mg、セルロース、着色剤、ラ
クトース、ステアリン酸マグネシウムおよびスターチ
と、保存剤としてブチル化ヒドロキシアニソールとを含
有する、ロバスタチン錠剤を製造する。かかるロバスタ
チン錠剤は、本発明に従って、実質的正常な血清コレス
テロール量を持つ患者の、二次心臓発作の危険を予防ま
たは軽減するため、単独で使用、またカプトプリル錠剤
(実施例5に記載)またはセラナプリル錠剤と、別個また
は混合投与の形式で併用使用することができる。Example 8 Containing 20 mg Lovastatin, Cellulose, Colorant, Lactose, Magnesium Stearate and Starch and Butylated Hydroxyanisole as Preservative, Using Conventional Pharmaceutical Techniques, in Accordance with the Description of "1990 PDR" To produce lovastatin tablets. Such lovastatin tablets are used alone or in accordance with the present invention to prevent or reduce the risk of secondary heart attacks in patients with substantially normal serum cholesterol levels, and captopril tablets.
It may be used in combination with (as described in Example 5) or seranapril tablets in the form of separate or mixed administrations.
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/38 A61K 31/38 31/40 31/40 31/415 31/415 31/66 31/66 38/55 45/06 ABN 45/06 ABN A61K 37/64 //(A61K 31/365 31:40) (72)発明者 ジョン・シー・アレキサンダー アメリカ合衆国60093イリノイ州ウィネト カ、ペルハム・ロード1100番Continuation of front page (51) Int.Cl. 6 Identification code Office reference number FI Technical display location A61K 31/38 A61K 31/38 31/40 31/40 31/415 31/415 31/66 31/66 38 / 55 45/06 ABN 45/06 ABN A61K 37/64 // (A61K 31/365 31:40) (72) Inventor John Sea Alexander United States 60093 Winnetka, Illinois 1100 Pelham Road
Claims (9)
リルコエンチームA(HMG CoA)レダクターゼの抑
制剤単独、または該抑制剤とアンギオテンシン変換酵素
(ACE)抑制剤との組合せから成ることを特徴とする、
実質的正常な血清コレステロール量を持つ哺乳動物の二
次心臓発作の危険の予防または軽減用組成物。1. An inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase alone, or the inhibitor and angiotensin converting enzyme.
(ACE) in combination with an inhibitor,
A composition for preventing or reducing the risk of a secondary heart attack in a mammal having a substantially normal serum cholesterol level.
剤が、メバスタチン、ロバスタチン、プラバスタチンま
たはベロスタチンである請求項1に記載の組成物。2. The composition according to claim 1, wherein the inhibitor of the enzyme HMG CoA reductase is mevastatin, lovastatin, pravastatin or verostatin.
剤が、メバロノラクトンのピラゾール類縁体、メバロノ
ラクトンのインデン類縁体、3−カルボキシ−2−ヒド
ロキシ−プロパン−ホスフィン酸誘導体、6−[2−(置
換ピロール−1−イル)アルキル]ピラン−2−オン、メ
バロノラクトンのイミダゾール類縁体、メバロノラクト
ンの複素環類縁体、メバロノラクトンのナフチル類縁
体、オクタヒドロ−ナフタレン、フルインドスタチン、
ロバスタチンのケト類縁体または2,3−ジ置換ピロー
ル、フランもしくはチオフェンである請求項1に記載の
組成物。3. The inhibitor of the enzyme HMG CoA reductase is a pyrazole analog of mevalonolactone, an indene analog of mevalonolactone, a 3-carboxy-2-hydroxy-propane-phosphinic acid derivative, 6- [2- (substituted pyrrole-1). -Yl) alkyl] pyran-2-one, imidazole analog of mevalonolactone, heterocyclic analog of mevalonolactone, naphthyl analog of mevalonolactone, octahydro-naphthalene, fluindostatin,
The composition of claim 1 which is a keto analog of lovastatin or a 2,3-disubstituted pyrrole, furan or thiophene.
剤がプラバスタチンである請求項1に記載の組成物。4. The composition according to claim 1, wherein the inhibitor of the enzyme HMG CoA reductase is pravastatin.
プリル、エナラプリル、セラノプリル、ホシノプリル、
リシノプリルまたはフェンチアプリルである請求項1に
記載の組成物。5. The ACE inhibitor is captopril, zofenopril, enalapril, seranopril, fosinopril,
The composition according to claim 1, which is lisinopril or fentiapril.
酸もしくはイミノ酸またはこれらの塩、プロリン誘導
体、置換プロリン誘導体、置換プロリンのメルカプトア
シル誘導体、カルボキシアルキルジペプチド誘導体、ホ
スフィニルアルカノイルプロリン誘導体またはホスホン
アミデート誘導体である請求項1に記載の組成物。6. The ACE inhibitor is a phosphonate-substituted amino acid or imino acid or a salt thereof, a proline derivative, a substituted proline derivative, a mercaptoacyl derivative of a substituted proline, a carboxyalkyl dipeptide derivative, a phosphinylalkanoyl proline derivative or a phosphonamidate derivative. The composition of claim 1 which is
剤がプラバスタチンで、ACE抑制剤がカプトプリル、
ホシノプリルまたはセラノプリルである請求項1に記載
の組成物。7. The inhibitor of the enzyme HMG CoA reductase is pravastatin and the ACE inhibitor is captopril,
The composition according to claim 1, which is hosinopril or selanopril.
項1に記載の組成物。8. The composition according to claim 1, wherein the mammal to be treated is normotensive.
こすのに必要な量よりも少ない請求項1に記載の組成
物。9. The composition according to claim 1, wherein the dose of the ACE inhibitor is less than the amount required to cause blood circulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US424984 | 1995-04-19 | ||
US08/424,984 US5622985A (en) | 1990-06-11 | 1995-04-19 | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08291082A true JPH08291082A (en) | 1996-11-05 |
Family
ID=23684677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8098084A Pending JPH08291082A (en) | 1995-04-19 | 1996-04-19 | Composition for prophylaxis of secondary cardioattack |
Country Status (10)
Country | Link |
---|---|
US (1) | US5622985A (en) |
EP (1) | EP0738512B1 (en) |
JP (1) | JPH08291082A (en) |
AT (1) | ATE244006T1 (en) |
AU (1) | AU715181B2 (en) |
CA (1) | CA2172884A1 (en) |
DE (1) | DE69628874T2 (en) |
DK (1) | DK0738512T3 (en) |
ES (1) | ES2202393T3 (en) |
PT (1) | PT738512E (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869499A (en) * | 1993-07-15 | 1999-02-09 | Pfizer Inc | Benzyloxyquinuclidines as substance P antagonists |
US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
CA2300165A1 (en) * | 1997-08-26 | 1999-03-04 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US6180660B1 (en) | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
EP1514543A1 (en) | 1997-08-29 | 2005-03-16 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
GT199800127A (en) | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. | |
US6147109A (en) * | 1997-10-14 | 2000-11-14 | The General Hospital Corporation | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
NZ508544A (en) * | 1998-06-05 | 2002-10-25 | Warner Lambert Co | Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide |
CA2335366A1 (en) * | 1998-06-24 | 1999-12-29 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
US6423751B1 (en) | 1998-07-14 | 2002-07-23 | The Brigham And Women's Hospital, Inc. | Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
US7141602B2 (en) * | 1998-09-18 | 2006-11-28 | Lek Pharmaceuticals D.D. | Process for obtaining HMG-CoA reductase inhibitors of high purity |
AU767154B2 (en) * | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
AU2007200367B2 (en) * | 1999-02-06 | 2010-04-08 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
SE9903028D0 (en) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
KR20020040795A (en) * | 1999-08-30 | 2002-05-30 | 로버트 흐라이탁, 미쉘 베스트 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
WO2001021259A2 (en) * | 1999-09-21 | 2001-03-29 | Emory University | Use and compositions for treating platelet-related disorders using anagrelide |
ES2328446T5 (en) | 2000-02-04 | 2014-02-27 | Children's Hospital Research Foundation | Use of lysosomal acid lipase to treat atherosclerosis and associated diseases |
EP1275388A4 (en) * | 2000-02-10 | 2003-11-26 | Takeda Chemical Industries Ltd | Tnf- alpha inhibitors |
WO2001078747A1 (en) * | 2000-04-18 | 2001-10-25 | Bayer Aktiengesellschaft | Use of cse inhibitors for treating heart failure |
US6689807B1 (en) * | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
EP1320362B1 (en) * | 2000-09-20 | 2011-08-31 | Jagotec AG | Stabilised fibrate microparticles |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
AU2002247019C1 (en) * | 2001-01-26 | 2017-05-11 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
US20020183383A1 (en) * | 2001-02-27 | 2002-12-05 | Rene Belder | Pharmaceutical compositions |
US6462174B1 (en) | 2001-06-25 | 2002-10-08 | Astrazeneca Ab | Amorphous compound |
US6627760B1 (en) | 2001-06-25 | 2003-09-30 | Astrazeneca Ab | Amorphous compound |
US6458769B1 (en) | 2001-06-25 | 2002-10-01 | Astrazeneca Ab | Amorphous compound |
US6576256B2 (en) | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
JP2005504091A (en) * | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | Treatment of xanthomas with azetidinone as a sterol absorption inhibitor |
US7107198B2 (en) * | 2001-11-02 | 2006-09-12 | Sun Microsystems, Inc. | Automatic generation of reduced-size circuit models including inductive interaction |
WO2003094856A2 (en) | 2002-05-09 | 2003-11-20 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
EP1585500B8 (en) | 2002-12-20 | 2017-07-26 | Auritec Pharmaceuticals | Coated particles for sustained-release pharmaceutical administration |
US20040168951A1 (en) * | 2003-02-27 | 2004-09-02 | Mackie Robert W. | Method and system for self administration of medications |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7208486B2 (en) * | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
BRPI0408442A (en) * | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | method for increasing the oral bioavailability of s- [2 - ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanothioate |
PT1603553E (en) * | 2003-03-17 | 2012-02-03 | Japan Tobacco Inc | Pharmaceutical compositions of cetp inhibitors |
TWI494102B (en) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor |
DE602004028469D1 (en) * | 2003-06-05 | 2010-09-16 | Univ Singapore | APPLICATIONS FROM IT |
BRPI0412557A (en) | 2003-07-28 | 2006-09-19 | Reddys Lab Inc Dr | pharmaceutical dosage form of cardiovascular events |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US6978908B2 (en) * | 2003-09-15 | 2005-12-27 | Gerber Products Company | Drinking vessel with adjustable handles |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
DE602005025755D1 (en) | 2004-06-04 | 2011-02-17 | Teva Pharma | IRBESARTAN PHARMACEUTICAL COMPOSITION CONTAINING |
EP2927693A1 (en) | 2004-10-06 | 2015-10-07 | The Brigham and Women's Hospital | Relevance of achieved levels of markers of systemic inflammation following treatment |
EP1848424B1 (en) * | 2005-01-31 | 2017-04-05 | Mylan Laboratories, Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
EP1982711A1 (en) | 2005-05-31 | 2008-10-22 | Mylan Laboratories, Inc | Compositions comprsing nebivolol |
US20070037797A1 (en) * | 2005-08-15 | 2007-02-15 | Hellstrom Harold R | Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events |
US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
ES2300188B1 (en) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | BICAPA COMPRESSED FOR THE PREVENTION OF CARDIOVASCULAR ACCIDENTS. |
WO2007146229A2 (en) | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
KR101455413B1 (en) * | 2006-08-30 | 2014-10-27 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | Pharmaceutical composition containing statin-encapsulated nanoparticle |
US20080118572A1 (en) * | 2006-10-10 | 2008-05-22 | Harold Richard Hellstrom | Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood |
WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
WO2008124122A1 (en) * | 2007-04-09 | 2008-10-16 | Scidose, Llc | Combinations of statins and anti-obesity agent and glitazones |
MX2009010925A (en) * | 2007-04-09 | 2009-11-02 | Scidose Llc | Combinations of statins and anti-obesity agent. |
EP2541254B1 (en) | 2007-04-18 | 2014-11-12 | Health Diagnostic Laboratory, Inc. | Diabetes-related biomarkers and methods of use thereof |
EP2531163A1 (en) | 2010-02-01 | 2012-12-12 | The Hospital For Sick Children | Remote ischemic conditioning for treatment and preventon of restenosis |
SG10201908570RA (en) | 2010-03-31 | 2019-11-28 | Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
EP2555692A2 (en) | 2010-04-08 | 2013-02-13 | The Hospital For Sick Children | Use of remote ischemic conditioning for traumatic injury |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
WO2014022195A1 (en) | 2012-08-01 | 2014-02-06 | Tavakoli Zahra | Free flowing, frozen compositions comprising a therapeutic agent |
EP2976062B1 (en) | 2013-03-21 | 2021-11-03 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
KR20180069055A (en) | 2015-10-27 | 2018-06-22 | 유프락시아 파마수티컬스 인코포레이티드 | Sustained release formulation of topical anesthetic |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK149080C (en) * | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
DE3536687A1 (en) * | 1985-10-15 | 1987-04-16 | Hoechst Ag | METHOD FOR TREATING ATHEROSCLEROSIS, THROMBOSIS AND PERIPHERAL VESSEL DISEASE |
US4920123A (en) * | 1988-10-21 | 1990-04-24 | Beyer Jr Karl H | Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals |
US5008284A (en) * | 1989-02-15 | 1991-04-16 | E. R. Squibb & Sons, Inc. | Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation |
CA2042526A1 (en) * | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
-
1995
- 1995-04-19 US US08/424,984 patent/US5622985A/en not_active Expired - Lifetime
-
1996
- 1996-03-28 CA CA002172884A patent/CA2172884A1/en not_active Abandoned
- 1996-04-18 DK DK96106104T patent/DK0738512T3/en active
- 1996-04-18 DE DE69628874T patent/DE69628874T2/en not_active Revoked
- 1996-04-18 EP EP96106104A patent/EP0738512B1/en not_active Revoked
- 1996-04-18 ES ES96106104T patent/ES2202393T3/en not_active Expired - Lifetime
- 1996-04-18 AU AU50741/96A patent/AU715181B2/en not_active Ceased
- 1996-04-18 PT PT96106104T patent/PT738512E/en unknown
- 1996-04-18 AT AT96106104T patent/ATE244006T1/en not_active IP Right Cessation
- 1996-04-19 JP JP8098084A patent/JPH08291082A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0738512B1 (en) | 2003-07-02 |
ATE244006T1 (en) | 2003-07-15 |
CA2172884A1 (en) | 1996-10-20 |
DE69628874T2 (en) | 2004-04-22 |
US5622985A (en) | 1997-04-22 |
ES2202393T3 (en) | 2004-04-01 |
AU715181B2 (en) | 2000-01-20 |
PT738512E (en) | 2003-11-28 |
EP0738512A1 (en) | 1996-10-23 |
DK0738512T3 (en) | 2003-10-06 |
AU5074196A (en) | 1996-10-31 |
DE69628874D1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08291082A (en) | Composition for prophylaxis of secondary cardioattack | |
US5190970A (en) | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor | |
US5130333A (en) | Method for treating type II diabetes employing a cholesterol lowering drug | |
US5140012A (en) | Method for preventing onset of restenosis after angioplasty employing pravastatin | |
US5461039A (en) | Method for treating hypertension employing a cholesterol lowering drug | |
USH1286H (en) | Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof | |
US5157025A (en) | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug | |
JPH04282324A (en) | Prophylactic agent against diabetes and its complications | |
US6248729B1 (en) | Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination | |
EP0457514B1 (en) | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
US5166143A (en) | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor | |
EP0461548A2 (en) | Method for preventing a second heart attack employing and HMG CoA reductase inhibitor | |
IE911779A1 (en) | Method for preventing onset of restenosis after angioplasty¹employing pravastatin | |
EP0477624A1 (en) | Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors | |
US6630502B2 (en) | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
JPH1081633A (en) | Medicinal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060822 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061003 |